Diego Nicolas Guacaneme, Claudio Alejando Jiménez Monsalve, Orlando Oliveros Pasión, Julieth Milena Rodríguez López, Neiry María Zapa Pérez, Hellen Kreinter, Nelly Daniela Gonzalez Galvis
Background: Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) is a rare, controversial and underdiagnosed entity characterized by an acute or subacute onset of encephalopathy. It is a diagnosis of exclusion with supporting criteria that include high titers of anti-thyroid antibodies, a history of Hashimoto's thyroiditis, and a good response to steroids. Case report: An 18-year-old female patient with hypothyroidism and episode of change in behavior, hallucinations and episodes of generalized tonic-clonic movements, normal skull tomography, cerebrospinal fluid with pleocytosis without signs of infection and positive anti-thyroid antibodies with adequate response to management with steroids Conclusion: We considered SERAT as an entity that needs to be rediscovered as it has conflicting results that question if it is a syndrome or a myth. The literature is especially lacking in Colombia where there are not many published cases.
{"title":"Steroid-Sensitive Encephalopathy Associated With Autoimmune Thyroiditis (SREAT): Case Report","authors":"Diego Nicolas Guacaneme, Claudio Alejando Jiménez Monsalve, Orlando Oliveros Pasión, Julieth Milena Rodríguez López, Neiry María Zapa Pérez, Hellen Kreinter, Nelly Daniela Gonzalez Galvis","doi":"10.35702/clinres.10017","DOIUrl":"https://doi.org/10.35702/clinres.10017","url":null,"abstract":"Background: Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) is a rare, controversial and underdiagnosed entity characterized by an acute or subacute onset of encephalopathy. It is a diagnosis of exclusion with supporting criteria that include high titers of anti-thyroid antibodies, a history of Hashimoto's thyroiditis, and a good response to steroids. Case report: An 18-year-old female patient with hypothyroidism and episode of change in behavior, hallucinations and episodes of generalized tonic-clonic movements, normal skull tomography, cerebrospinal fluid with pleocytosis without signs of infection and positive anti-thyroid antibodies with adequate response to management with steroids Conclusion: We considered SERAT as an entity that needs to be rediscovered as it has conflicting results that question if it is a syndrome or a myth. The literature is especially lacking in Colombia where there are not many published cases.","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136083583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pyrimidine is one of aromatic heterocyclic class of organic compounds that’s similar to pyridine. It’s found in the nucleic acids DNA and RNA. Novel pyrimidinic selenoureas were reported to have a remarkable inhibitory activity against breast carcinoma cells (MCF-7). With the help of computer-aided drug design techniques one of these of compounds was further optimized to design three other derivatives with more potency than the previous and also more potent than many anti-breast cancer drugs. The main aim of this study was to design more potent pyrimidinic selenoureas derivatives and compare them with the standard anti-breast cancer drugs. An optimization method of structure-based drug design was employed. Two compounds of novel pyrimidinic selenoureas were reported in which the first compound was selected and docked with the ERBB2 receptor tyrosine kinase (PDB ID: 2A91), it was then modified to design three (3) derivatives. The receptors were later docked with seven (7) different anti-breast cancer drugs approved by American Cancer Society (such as, Capecitabine, Cisplatin, Curcumin, Paclitaxel, Ixabepilone, Doxorubicin and Vinorelbine) to record their potency and later compared with the designed compounds. An ADMET pharmacokinetic study was carried out on the designed compounds to investigate their drug-likeness. In the result, all the designed compounds were found to be more potent than the template, in which compound a1 and a2 (with moldock score of -148.456 and -153.725) were found to be more potent than Capecitabine, Cisplatin, Curcumin, Doxorubicin and Vinorelbine (moldock score; -134.953, -43.889, -148.290, -106.187 and -134.986), but less active than Paclitaxel and Ixabepilone (with moldock scores of -154.135 and -157.093), with compound a3 (moldock score; -161.583) recorded the highest potency which is more potent than all the listed drugs, and also the designed compounds were found to have good pharmacokinetic profiles. Conclusively, three other derivatives of novel pyrimidinic selenoureas were designed and found to be more potent than the template and many anti-breast cancer drugs. The compounds should be further synthesized for their excellent activities and good pharmacokinetic parameters.
{"title":"In Silico Discovery and ADMET Pharmacokinetic of Novel Pyrimidinic Selenoureas as Selective Breast Carcinoma Cells (MCF-7) Inhibitors","authors":"Yusuf Isyaku, Adamu Uzairu, Aliyu Muhammad Ja'o","doi":"10.35702/clinres.10016","DOIUrl":"https://doi.org/10.35702/clinres.10016","url":null,"abstract":"Pyrimidine is one of aromatic heterocyclic class of organic compounds that’s similar to pyridine. It’s found in the nucleic acids DNA and RNA. Novel pyrimidinic selenoureas were reported to have a remarkable inhibitory activity against breast carcinoma cells (MCF-7). With the help of computer-aided drug design techniques one of these of compounds was further optimized to design three other derivatives with more potency than the previous and also more potent than many anti-breast cancer drugs. The main aim of this study was to design more potent pyrimidinic selenoureas derivatives and compare them with the standard anti-breast cancer drugs. An optimization method of structure-based drug design was employed. Two compounds of novel pyrimidinic selenoureas were reported in which the first compound was selected and docked with the ERBB2 receptor tyrosine kinase (PDB ID: 2A91), it was then modified to design three (3) derivatives. The receptors were later docked with seven (7) different anti-breast cancer drugs approved by American Cancer Society (such as, Capecitabine, Cisplatin, Curcumin, Paclitaxel, Ixabepilone, Doxorubicin and Vinorelbine) to record their potency and later compared with the designed compounds. An ADMET pharmacokinetic study was carried out on the designed compounds to investigate their drug-likeness. In the result, all the designed compounds were found to be more potent than the template, in which compound a1 and a2 (with moldock score of -148.456 and -153.725) were found to be more potent than Capecitabine, Cisplatin, Curcumin, Doxorubicin and Vinorelbine (moldock score; -134.953, -43.889, -148.290, -106.187 and -134.986), but less active than Paclitaxel and Ixabepilone (with moldock scores of -154.135 and -157.093), with compound a3 (moldock score; -161.583) recorded the highest potency which is more potent than all the listed drugs, and also the designed compounds were found to have good pharmacokinetic profiles. Conclusively, three other derivatives of novel pyrimidinic selenoureas were designed and found to be more potent than the template and many anti-breast cancer drugs. The compounds should be further synthesized for their excellent activities and good pharmacokinetic parameters.","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135005110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G A Sachs, C B Stocking, R Stern, D M Cox, G Hougham, R S Sachs
{"title":"Ethical aspects of dementia research: informed consent and proxy consent.","authors":"G A Sachs, C B Stocking, R Stern, D M Cox, G Hougham, R S Sachs","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"42 3","pages":"403-12"},"PeriodicalIF":0.0,"publicationDate":"1994-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18951625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cancer risk research: what should we tell subjects?","authors":"E Kodish, T H Murray, S Shurin","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"42 3","pages":"396-402"},"PeriodicalIF":0.0,"publicationDate":"1994-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18951624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The First Lady addresses the NIH. February 17, 1994.","authors":"H Rodham Clinton","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"42 2","pages":"156-60"},"PeriodicalIF":0.0,"publicationDate":"1994-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19177451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The ethical conduct of health services research: a case study of 55 institutions' applications to the SUPPORT project.","authors":"J Lynn, J Johnson, R J Levine","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"42 1","pages":"3-10"},"PeriodicalIF":0.0,"publicationDate":"1994-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19189865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The impact of DNR orders on CPR research: educational and ethical implications.","authors":"J P Orlowski","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"41 4","pages":"595-600"},"PeriodicalIF":0.0,"publicationDate":"1993-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19104292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Problems with stopping rules in the trials of risky therapies: the case of warfarin to prevent stroke in atrial fibrillation.","authors":"D E Singer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10429,"journal":{"name":"Clinical research","volume":"41 3","pages":"482-6"},"PeriodicalIF":0.0,"publicationDate":"1993-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19389301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：